Tysabri and Progressive Multifocal Leukoencephalopathy: Legal Considerations in California

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Occupational and Therapeutic Risk

The legacy of mass production in the automotive industry has long been intertwined with public health and safety considerations. Historically, general health and science information disseminated to the public emphasized the importance of understanding environmental and occupational exposures, from industrial chemicals to manufacturing byproducts. This foundational awareness has shaped how we approach risk assessment in production environments, where workers and consumers alike may encounter substances requiring careful monitoring. As we pivot from this broad health context to a more specific occupational exposure concern, it becomes essential to recognize that certain therapeutic agents used in medical treatment can also present risks in production settings. For instance, the manufacturing and handling of biologic drugs like Tysabri involve exposure to active pharmaceutical ingredients that may carry potential hazards. Among these, the risk of progressive multifocal leukoencephalopathy (PML) has been identified as a serious consideration for individuals involved in the production chain. This transition from general health education to targeted occupational vigilance underscores the need for clear protocols and legal awareness, particularly regarding statutes of limitations for claims related to such exposures in jurisdictions like California.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn’s disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, but Tysabri-treated patients have developed the disease even in the absence of other immunosuppressive conditions. Three established risk factors for PML in Tysabri-treated patients include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment. The drug is available only through a restricted distribution program called the TOUCH Prescribing Program, which requires patients to be enrolled, read a Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals must monitor patients for any new sign or symptom suggestive of PML and withhold Tysabri immediately at the first indication of the disease.

Clinical Presentation and Diagnostic Challenges

The clinical presentation of PML can be subtle and may include progressive neurological deficits such as weakness, gait disturbance, cognitive decline, visual changes, or speech difficulties. These symptoms overlap with those of multiple sclerosis relapses, which can complicate diagnosis. In the FDA Adverse Event Reporting System (FAERS), the most frequently reported adverse events associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, balance disorder, hypoesthesia, muscular weakness, cognitive disorder, and depression (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they illustrate the range of neurological symptoms that may be reported by patients and that could potentially mask or mimic early PML. The mechanistic pathway linking Tysabri to PML involves the drug’s action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrins on the surface of immune cells, preventing their adhesion to endothelial cells and subsequent migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system, which is beneficial in multiple sclerosis, but it also impairs immune surveillance against JCV. Under normal conditions, JCV is controlled by the immune system, but when T-cell trafficking to the brain is reduced, the virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML.

Timeline of Exposure and Legal Implications in California

For patients who develop PML after Tysabri exposure, the timeline between initiation of therapy and documented harm can vary. The boxed warning notes that longer treatment duration, especially beyond two years, is a known risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, cases have been reported after shorter durations. The prescribing information also warns about herpes encephalitis and meningitis, with onset ranging from a few months to several years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), indicating that infectious complications can emerge at various points during treatment. From a legal perspective, patients in California who have been harmed by Tysabri-associated PML may have claims based on inadequate warnings. The boxed warning explicitly states the risk of PML and identifies risk factors, but questions may arise about whether the warnings were sufficiently communicated to patients and healthcare providers, especially before the drug was prescribed. The TOUCH program is designed to ensure informed consent, but if a patient was not adequately informed of the specific risk factors—such as the significance of anti-JCV antibody status or the increased risk after two years of treatment—the adequacy of the warning may be challenged. The statute of limitations for product liability claims in California generally requires that a lawsuit be filed within two years from the date the plaintiff discovered, or through reasonable diligence should have discovered, the injury and its cause. For PML, this can be complex because symptoms may initially be attributed to multiple sclerosis rather than to the drug. The timeline between exposure and documented harm is critical: if a patient received Tysabri for several years before developing PML, the date of diagnosis or the date when symptoms became clearly distinguishable from the underlying disease may serve as the starting point for the limitations period. Patients and their families should consult with an attorney experienced in pharmaceutical litigation to evaluate their specific circumstances and ensure timely filing.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in California?

In California, the statute of limitations for product liability claims generally requires filing a lawsuit within two years from the date the plaintiff discovered, or through reasonable diligence should have discovered, the injury and its cause. For PML, this can be complex because symptoms may initially be attributed to multiple sclerosis rather than to the drug. The date of diagnosis or when symptoms became clearly distinguishable from the underlying disease may serve as the starting point. Consulting an attorney is recommended to evaluate specific circumstances.

What are the risk factors for developing PML while on Tysabri?

Three established risk factors for PML in Tysabri-treated patients include the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.